In a patient taking amlodipine‑benazepril and olmesartan who now has hyperkalemia (serum potassium 6 mmol/L) and is being started on Lokelma (sodium zirconium cyclosilicate), which antihypertensive medication should replace olmesartan?

Replace Olmesartan with a Dihydropyridine Calcium Channel Blocker

In this patient with severe hyperkalemia (K+ 6.0 mmol/L) on dual RAAS blockade (benazepril + olmesartan), you should discontinue olmesartan and replace it with a dihydropyridine calcium channel blocker such as amlodipine (which the patient is already receiving as part of the amlodipine-benazepril combination), or add/increase a thiazide-type diuretic if additional blood pressure control is needed.

Rationale for Discontinuing Dual RAAS Blockade

Your patient is currently on inappropriate dual RAAS inhibition with both an ACE inhibitor (benazepril) and an ARB (olmesartan). This combination significantly increases hyperkalemia risk and is explicitly contraindicated by current guidelines 1, 2. The 2017 ACC/AHA guidelines state clearly: "Do not use in combination with ACE inhibitors" for ARBs 1.

Both drug classes cause hyperkalemia through the same mechanism—inhibition of aldosterone, which reduces renal potassium excretion 3, 4. The FDA labels for both olmesartan and amlodipine-benazepril warn that "drugs that inhibit the renin angiotensin system can cause hyperkalemia" with risk factors including "renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes" 3, 4.

Immediate Management Steps

1. Discontinue olmesartan immediately while continuing the amlodipine-benazepril combination
2. Continue Lokelma (sodium zirconium cyclosilicate) for acute and maintenance hyperkalemia management 5, 6, 7
3. Monitor potassium closely: Check levels 2-4 weeks after medication changes 8
4. Maintain the ACE inhibitor (benazepril) as monotherapy for RAAS inhibition, as these agents provide proven cardiovascular and renal benefits 1

Alternative Antihypertensive Options

If additional blood pressure control is needed after discontinuing olmesartan, the 2017 ACC/AHA guidelines recommend 1, 2:

First-line alternatives (in order of preference):

• Thiazide-type diuretics (chlorthalidone 12.5-25 mg daily preferred over hydrochlorothiazide 25-50 mg daily) - These actually help lower potassium and complement ACE inhibitor therapy 1, 9
• Additional dihydropyridine CCB if not already at maximum amlodipine dose (can increase to 10 mg daily) 1
• Long-acting dihydropyridine CCBs such as nifedipine LA 30-90 mg daily 1

Avoid:

• Potassium-sparing diuretics (amiloride, triamterene, spironolactone, eplerenone) - contraindicated with K+ >5.5 mmol/L 10, 1
• Any additional RAAS inhibitor (another ARB, direct renin inhibitor) 1

Role of Lokelma in Ongoing Management

Lokelma (SZC) is appropriate for both acute and chronic hyperkalemia management 5, 6, 7. Recent evidence shows:

• Rapid potassium reduction: SZC significantly lowers potassium within 48-72 hours (WMD -0.45 mEq/L) 6
• Sustained control: Maintains normokalaemia with once-daily dosing (5-10g) 5, 6
• Enables RAAS optimization: Allows continuation of guideline-directed ACE inhibitor therapy 11, 12, 7

However, SZC does not justify continuing dual RAAS blockade, which remains contraindicated regardless of potassium binder use 1.

Monitoring Protocol

After discontinuing olmesartan 8:

1. Check potassium and creatinine at 1 week
2. Recheck at 2-4 weeks after any dose adjustments
3. If potassium normalizes, continue monitoring every 3-6 months
4. Watch for potassium >5.5 mmol/L (reduce ACE inhibitor dose by 50%) or >6.0 mmol/L (hold ACE inhibitor temporarily) 10

Common Pitfall to Avoid

Do not simply reduce the dose of both RAAS agents—this maintains the contraindicated combination and inadequately addresses the hyperkalemia risk. Complete discontinuation of one agent (olmesartan) is required 1.